Cov-hep研究:COVID-19合并急性肾损伤患者枸橼酸抗凝连续性静脉-静脉血液透析中加用肝素的研究方案随机对照试验结构化摘要
本研究为随机、平行组、开放标签试验,在巴西圣保罗大学综合医院ICU开展,拟纳入90例确诊COVID-19合并需透析的急性肾损伤成人患者,按1:1随机分为枸橼酸抗凝组与枸橼酸联合普通肝素组,主要比较72小时内透析器凝血百分比,并评估出血、血小板减少等安全性指标。
要点
- 在枸橼酸抗凝基础上加用普通肝素10 U/Kg/h,旨在减少COVID-19透析患者滤器凝血损失。
- 主要结局为72小时内凝血透析器百分比,次要结局包括出血事件与血小板减少比例。
- 排除枸橼酸中毒风险者(乳酸>30 mg/dL、INR>2.5、总胆红素>15 mg/dL)及24小时内可能死亡者。
核心结论
- 该研究旨在验证枸橼酸抗凝基础上加用肝素能否减少COVID-19合并急性肾损伤透析患者的透析回路凝血损失,且不增加血小板减少或出血风险。
研究设计与样本
- 随机、平行组、开放标签试验,两臂按1:1比例比较不同连续性肾脏替代治疗抗凝策略。
- 计划纳入90例患者(每组45例),在巴西圣保罗大学综合医院ICU开展。
- 随机化采用RedCap系统,按D-二聚体水平(切点5000 ng/dL)和导管部位(右颈内静脉与其他部位)进行2个区组随机。
- 试验版本2.0,首例招募日期2020年6月29日,预计最后招募日期2020年12月31日。
关键数值与推荐
- 干预组:连续性血液透析(血流150 mL/min,剂量30 mL/Kg/h)接受枸橼酸钠4 mmol/L抗凝联合普通肝素10 U/Kg/h。
- 对照组:连续性肾脏替代治疗(血流150 mL/min,剂量30 mL/Kg/h)接受枸橼酸钠4 mmol/L抗凝。
- 主要结局:每组72小时内凝血透析器的百分比。
- 轻度出血定义为无临床影响或血红蛋白下降<1 g/dL的出血事件;重度出血定义为有临床影响或血红蛋白下降>1 g/dL的出血事件。
临床怎么用
- 针对确诊COVID-19合并急性肾损伤需透析的ICU成人患者(>18岁),在标准枸橼酸抗凝基础上可考虑联合普通肝素10 U/Kg/h以维持滤器通畅。
局限性
- 开放标签设计,未设盲。
- 单中心研究,样本量90例。
- 排除24小时内可能死亡者及枸橼酸中毒高风险患者,外推受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The primary objective is to test if heparin added to a standard regional anticoagulation protocol based on citrate is able to reduce dialysis circuit losses by clotting without increasing the risk of thrombocytopenia or bleeding, in patients with COVID-19 with acute kidney injury requiring dialysis. TRIAL DESIGN: Randomized, parallel-group, open-label trial, with two arms (ratio 1:1) comparing different continuous renal replacement therapy anticoagulation strategies. PARTICIPANTS: Eligibility conditions: All ICU patients of University of Sao Paulo General Hospital (Hospital das Clínicas), Brazil will be screened for eligibility conditions. Adults (> 18 years old) with confirmed COVID-19 and acute kidney injury requiring dialysis with agreement between ICU and nephrology teams for the introduction of renal continuous replacement therapy in daily ICU rounds. Continuous renal replacement therapy will be prescribed by consulting nephrologists based on standard clinical guidelines, including acute kidney injury with hemodynamic instability plus hyperkalemia, severe acidosis, volume overload, respiratory distress, multiorgan failure or some combination of these factors. DATA COLLECTION: Patients demographics and associated clinical data and comorbidities will be recorded at ICU entry. Demographic information will include the patient's age, sex, and admission dates. Clinical data comprise comorbidities, APACHE 2, SAPS 3, need for mechanical ventilation, and use of vasopressor drugs. Physiological data collected by the day of CRRT start will be vital signs, the arterial oxygen tension/fraction of inspired oxygen (PaO2/FiO2) index, and serum creatinine, blood urea nitrogen, bilirubin, hemoglobin, hematocrit, platelets, white blood cell count levels and Peak D-dimer levels. Patients will be analyzed for the first 72h of CRRT, and they will be evaluated regarding clinical variables, filter patency and any adverse events that could be related to the anticoagulation choice, as bleeding (mild or major) or low platelets counts (<100.000 ui/uL) during treatment period. Mild and major bleeding will be defined by hemorrhagic event without clinical impact or hemoglobin (Hb) fall lesser than 1g/dL and hemorrhagic event with clinical impact or Hb fall higher than 1g/dL, respectively. EXCLUSION CRITERIA: Hypersensitivity to any of the substances going to be used in the study (Citric acid dextrosol 2.2% and unfractionated heparin); Previous diagnosis of coagulopathy or thrombophilia; Contraindication to the use of unfractionated heparin; Risk of citrate poisoning - (Lactate> 30 mg/dL, international normalized ratio > 2.5, Total bilirubin> 15 mg/dL); Pregnancy; Patients unlikely to survive for more than 24 hours. The trial is being undertaken at the University of Sao Paulo General Hospital (Hospital das Clinicas), Brazil. INTERVENTION AND COMPARATOR: Group A (control) - Patients on continuous renal replacement therapy (blood flow 150 ml/min, dose of 30 mL/Kg/h) receiving anticoagulation with sodium citrate at 4 mmol/L Group B (experiment): Patients on continuous hemodialysis (blood flow 150 mL/min, dose of 30 mL/Kg/h) receiving anticoagulation with sodium citrate at 4 mmol/L associated with unfractionated heparin at 10 U/Kg/h. MAIN OUTCOMES: The percentage of clotted dialyzers within 72 hours in each of the studied groups (Primary outcome) Secondary outcomes: Number of dialyzers used in the first 72 hours of dialysis protocol, Mortality in the first 72 h of dialysis protocol, Bleeding events (Major or minor) in the first 72 h of dialysis protocol, Thrombocytopenia (less than 50.000 platelets) proportion in the first 72 h of dialysis protocol, Dialysis efficiency (Urea sieving) - variation in urea sieving between the first, second and third days of dialysis protocol, Continuous renal replacement therapy pressures (Arterial, Venous, dialysate and pre-filter pressure) in the first 72 h of dialysis protocol, in-hospital mortality. RANDOMIZATION: RedCap→ randomization - 2 blocks randomization by D-dimer level (5000ng/dL cut-off) and catheter site (Right Internal Jugular versus other sites) with 1:1 allocation ratio. BLINDING (MASKING): No blinding - Open label format NUMBERS TO BE RANDOMIZED (SAMPLE SIZE): Total number of patients 90 (45 per group) TRIAL STATUS: Trial version 2.0 - ongoing recruitment. First recruitment: June 29, 2020 Estimated date for last recruitment: December 31, 2020 TRIAL REGISTRATION: Responsible Party: University of Sao Paulo General Hospital (Hospital das Clinicas) ClinicalTrials.gov Identifier: NCT04487990 , registered July 27, 2020, ReBec www.ensaiosclinicos.gov.br/rg/RBR-45kf9p/ Other Study ID Numbers: U1111-1252-0194 FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1) In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
引用
- Lins PRG, de Albuquerque CCC, Assis CF, et al. Cov-hep study: heparin in standard anticoagulation based on citrate for continuous veno-venous hemodialysis in patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial. Trials. 2020. PMID: 33176886. doi:10.1186/s13063-020-04814-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。